Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca
Shots:
- Eccogene has reported the first patient dosing under the P-IIb clinical evaluation of ECC5004/AZD5004. AstraZeneca will pay $60M milestone for the same
- The P-IIb studies include VISTA (NCT06579092) and SOLSTICE (NCT06579105) evaluating the safety & efficacy of ECC5004/AZD5004 (QD, oral) for the treatment of obesity with at least one weight-related comorbidity and T2D
- AstraZeneca secured global rights to ECC5004/AZD5004 from Eccogene under an agreement in Nov 2023, with Eccogene receiving $185M upfront and entitled to receive up to $1.825B milestones plus royalties. Eccogene retains co-development & co-commercialization rights in China
Ref: Global Newswire | Image: Eccogene
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
